Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Brain glucagon-like peptide–1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage
Claude Knauf, … , Catherine Postic, Rémy Burcelin
Claude Knauf, … , Catherine Postic, Rémy Burcelin
Published December 1, 2005
Citation Information: J Clin Invest. 2005;115(12):3554-3563. https://doi.org/10.1172/JCI25764.
View: Text | PDF
Research Article Metabolism Article has an altmetric score of 3

Brain glucagon-like peptide–1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage

  • Text
  • PDF
Abstract

Intestinal glucagon-like peptide–1 (GLP-1) is a hormone released into the hepatoportal circulation that stimulates pancreatic insulin secretion. GLP-1 also acts as a neuropeptide to control food intake and cardiovascular functions, but its neural role in glucose homeostasis is unknown. We show that brain GLP-1 controlled whole-body glucose fate during hyperglycemic conditions. In mice undergoing a hyperglycemic hyperinsulinemic clamp, icv administration of the specific GLP-1 receptor antagonist exendin 9–39 (Ex9) increased muscle glucose utilization and glycogen content. This effect did not require muscle insulin action, as it also occurred in muscle insulin receptor KO mice. Conversely, icv infusion of the GLP-1 receptor agonist exendin 4 (Ex4) reduced insulin-stimulated muscle glucose utilization. In hyperglycemia achieved by i.v. infusion of glucose, icv Ex4, but not Ex9, caused a 4-fold increase in insulin secretion and enhanced liver glycogen storage. However, when glucose was infused intragastrically, icv Ex9 infusion lowered insulin secretion and hepatic glycogen levels, whereas no effects of icv Ex4 were observed. In diabetic mice fed a high-fat diet, a 1-month chronic i.p. Ex9 treatment improved glucose tolerance and fasting glycemia. Our data show that during hyperglycemia, brain GLP-1 inhibited muscle glucose utilization and increased insulin secretion to favor hepatic glycogen stores, preparing efficiently for the next fasting state.

Authors

Claude Knauf, Patrice D. Cani, Christophe Perrin, Miguel A. Iglesias, Jean François Maury, Elodie Bernard, Fadilha Benhamed, Thierry Grémeaux, Daniel J. Drucker, C. Ronald Kahn, Jean Girard, Jean François Tanti, Nathalie M. Delzenne, Catherine Postic, Rémy Burcelin

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 Total
Citations: 2 5 3 6 1 5 5 5 7 10 9 9 7 8 10 6 6 12 1 2 1 120
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2008 (12)

Title and authors Publication Year
Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake
DA Sandoval, D Bagnol, SC Woods, DA D'Alessio, RJ Seeley
Diabetes 2008
CNS GLP-1 regulation of peripheral glucose homeostasis
D Sandoval
Physiology & Behavior 2008
Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation
MR Hayes, KP Skibicka, HJ Grill
Endocrinology 2008
Brain Glucagon-Like Peptide-1 Regulates Arterial Blood Flow, Heart Rate, and Insulin Sensitivity
C Cabou, G Campistron, N Marsollier, C Leloup, C Cruciani-Guglielmacci, L Penicaud, DJ Drucker, C Magnan, R Burcelin
Diabetes 2008
Role of Central Nervous System Glucagon-Like Peptide-1 Receptors in Enteric Glucose Sensing
C Knauf, PD Cani, DH Kim, MA Iglesias, C Chabo, A Waget, A Colom, S Rastrelli, NM Delzenne, DJ Drucker, RJ Seeley, R Burcelin
Diabetes 2008
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
W Kim, JM Egan
Pharmacological reviews 2008
Central control of body weight and appetite
SC Woods, DA D'Alessio
The Journal of clinical endocrinology and metabolism 2008
The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action
JE Ayala, DP Bracy, FD James, BM Julien, DH Wasserman, DJ Drucker
Endocrinology 2008
Chronic inhibition of dipeptidyl peptidase-IV with ASP8497 improved the HbA1c level, glucose intolerance, and lipid parameter level in streptozotocin–nicotinamide-induced diabetic mice
A Matsuyama-Yokono, A Tahara, R Nakano, Y Someya, M Hayakawa, M Shibasaki
Naunyn-Schmiedeberg's Archives of Pharmacology 2008
Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety
DL Williams, DG Baskin, MW Schwartz
Endocrinology 2008
Paying the price for eating ice cream: is excessive GLP-1 signaling in the brain the culprit?
HR Berthoud
Endocrinology 2008
Bringing Light to the Dark Side of Insulin: A Journey Across the Blood-Brain Barrier
RS Sherwin
Diabetes 2008

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 4 patents
136 readers on Mendeley
See more details